Redeye provides a research update following the Q2 2024 report from Respiratorius. We postpone the estimated timing of a licensing deal to 2025e and provide an overview of the sentiment in the biopharma deal landscape. We also make minor other changes related to the valuation, resulting in a reduced fair value range.

Länk till analysen